United States - English - NLM (National Library of Medicine)

alk-abello a s - ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3) - ambrosia artemisiifolia pollen 12 [amb'a'1'u] - ragwitek® is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific ige antibodies for short ragweed pollen. ragwitek is approved for use in persons 5 through 65 years of age. ragwitek is not indicated for the immediate relief of allergic symptoms. ragwitek is contraindicated in patients with: - severe, unstable or uncontrolled asthma - a history of any severe systemic allergic reaction - a history of any severe local reaction after taking any sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product [see description ( 11 )]. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarr

Canada - English - Health Canada

alk-abello a/s - standardized short ragweed pollen allergenic extract - tablet (orally disintegrating) - 12unit - standardized short ragweed pollen allergenic extract 12unit - allergenic extracts

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3) - ambrosia artemisiifolia pollen 12 [amb'a'1'u]

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

alkem laboratories (pty) ltd - #n/a - not indicated - none

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

alkem laboratories (pty) ltd - #n/a - not indicated - none